Is Stryker Corp (SYK) undervalued or overvalued?

Our model estimates a fair value of about $272 against a price of $294.66 (Fair, -8% to fair value). It blends a 10-year DCF, sector multiples and earnings-power value and is a model estimate, not advice.

What is the X-Ray Score for SYK?

Stryker Corp has an X-Ray Score of 56 out of 100, built from valuation, growth, profitability, financial health and dividend lenses ranked against Health Care peers.

Where does the data for SYK come from?

Financial statements come from SEC EDGAR filings, prices from exchange price feeds, and industry betas and equity risk premium from Damodaran Online (NYU Stern).

Stryker Corp (SYK)

Health Care · Health Care Equipment · US stock · S&P 500 component

$294.66 ▲ +1.43 (0.49%)

At close 16 Oct 2026 · USD · Volume 3,377,300

Compare with RMD Historical data Research report SEC filings

Fair valueFair

$272 −7.6% to fair value

$136fair band $191–$354$408

Day's range

$293.75 – $299.67

52-week range

$266.16 – $388.25

About Stryker Corp

Stryker is a medical technology company that makes orthopedic implants, surgical equipment, neurotechnology products and hospital beds and emergency care devices. It is known for joint replacement products and its Mako surgical robot. Revenue comes from selling implants, instruments and capital equipment to hospitals and surgical centers worldwide, along with service and disposable products used in procedures.

The company reported revenue of $25.8 billion over the last twelve months. Across three years, revenue grew 10.8% a year. It posts an operating margin of 21.4%, with return on invested capital of 11%. Leverage, measured as net debt to EBITDA, is 1.6 times. The dividend yield is 1.2%. Overall, the X-Ray Score comes to 55 out of 100.

Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.

Price chart

Historical data & CSV

52-wk range $266.16 – $388.25Volume 3,377,300Daily, split-adjusted

Vitals

Market cap$113.7B

52-week range$266.16 – $388.25

Volume (last day)3,377,300

P/E (TTM)30.5

EBIT / EV yield4.4%

Free-cash-flow yield4.1%

Dividend yield1.2%

Revenue (TTM)$25.8B

Net income (TTM)$3.7B

Operating margin21.4%

Return on capital11.2%

Debt incl. leases$15.2B

Cash & securities$3.5B

Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.

Fair value estimate

$272model spread $258 – $289

Fair −7.6% to fair value

Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.

Price $295

Undervalued < $191Fair $191 – $354Overvalued > $354

10-year DCF (market-scaled)

$259

Peer multiples

$266

Earnings power floor (not blended)

$67

Fundamentals-adjusted multiple

$292

Growth the price implies

17.4%/yr

A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.

What this means

Average business, fairly priced

The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.

Before you invest · decision checklist

I understand how this company makes money Business quality is average or better ✓ 51 The price is not above fair value $272 fair value Debt looks manageable 1.6× EBITDA Revenue has been growing 10.8% a year Profits are backed by cash There are no red flags none raised I know what share of my savings this would be

Ticked boxes are filled in from our data; the rest are yours to answer.

The five-lens scan

Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.

Valuation Weak

48/100

Expensive against its sector on earnings and cash flow.

See the numbers →

EBIT / EV yield4.4%

Free-cash-flow yield4.1%

Fair value vs price0.9×

Growth Strong

74/100

Growing faster than most of its sector.

See the numbers →

Revenue growth (3y)10.8%

EPS growth (3y)10.8%

Growth consistency100%

Profitability Fair

55/100

Returns on capital are typical for its sector.

See the numbers →

Return on invested capital11.2%

Operating margin21.4%

Gross profitability35.0%

Financial health Weak

46/100

Balance sheet is more stretched than most peers.

See the numbers →

Piotroski F-Score4 / 9

Net debt / EBITDA1.6×

Interest cover9.2×

Dividends Fair

57/100

Dividend is typical for its sector.

See the numbers →

Dividend yield1.2%

Dividends vs free cash flow29%

Dividend growth6.9%

Quarterly results: last 6 quarters

+11.9%

Mar '25

+11.1%

Jun '25

+10.2%

Sep '25

+11.4%

Dec '25

+2.6%

Mar '26

+9.4%

Jun '26

Revenue against the same quarter a year earlier. Latest quarter revenue $6.6B, diluted EPS $3.30.

Compare with peers

RMD Resmed Inc73 DXCM Dexcom Inc71 PODD Insulet Corp69 IDXX Idexx Laboratories Inc67

Other Health Care Equipment companies by X-Ray Score.

Fundamentals checklist

● 5 Good · ● 10 Average · ● 1 Bad

Cash quality

Earnings backed by cashAverage

Free-cash-flow yieldAverage

Risk models

Altman Z''Average

Piotroski F-ScoreBad

Growth

EPS growth (3y)Average

Free-cash-flow growth (3y)Good

Revenue growth (3y)Good

Growth consistencyGood

Balance sheet

Current ratioGood

Net debt / EBITDAAverage

Interest coverAverage

Valuation

Fair value vs priceAverage

EBIT / EV yieldAverage

Profitability

Return on invested capitalAverage

Operating marginGood

Gross profitabilityAverage

Each check is graded against the company's sector, not a fixed number. Checklist score 58/100.

Financials

	FY21	FY22	FY23	FY24	FY25
Revenue	$17.1B	$18.4B	$20.5B	$22.6B	$25.1B
Operating income	$2.6B	$2.8B	$3.9B	$3.7B	$4.9B
Net income	$2.0B	$2.4B	$3.2B	$3.0B	$3.2B
Operating cash flow	$3.3B	$2.6B	$3.7B	$4.2B	$5.0B
Operating margin	15.1%	15.4%	19.0%	16.3%	19.5%
Free cash flow	$2.7B	$2.0B	$3.1B	$3.5B	$4.3B
Diluted EPS	$5.21	$6.17	$8.25	$7.76	$8.40

Fiscal years, from SEC filings.

Technical summary

Daily

Bearish

6 bullish · 1 neutral · 9 bearish

Weekly

Strongly bearish

1 bullish · 1 neutral · 10 bearish

Monthly

Strongly bearish

0 bullish · 1 neutral · 7 bearish

Moving averages (daily)

SMA 10	282.8	Bullish
EMA 10	284.2	Bullish
SMA 20	278.2	Bullish
EMA 20	283.4	Bullish
SMA 50	299.2	Bearish
EMA 50	293.4	Bullish
SMA 100	308.4	Bearish
EMA 100	305.3	Bearish
SMA 200	324.8	Bearish
EMA 200	320.2	Bearish

Oscillators (daily)

RSI (14)	59.08	Neutral
MACD (12, 26)	-1.53	Bearish
Momentum (12)	7.00	Bullish
Stochastic %K (14)	82.40	Bearish
Williams %R (14)	-17.60	Bearish
CCI (20)	253.2	Bearish

Pivot points (classic, last session)

286.5

290.1

292.4

Pivot

296.0

298.3

301.9

304.2

Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Dividends

Paid, last 12 months

3.52 USD

Yield on today's price

1.19%

Frequency

Quarterly

Next ex-dividend date

Not announced

Ex-dividend date	Amount per share
30 Sep 2026	0.8800
30 Jun 2026	0.8800
31 Mar 2026	0.8800
31 Dec 2025	0.8800
30 Sep 2025	0.8400
30 Jun 2025	0.8400
31 Mar 2025	0.8400
31 Dec 2024	0.8400
30 Sep 2024	0.8000
28 Jun 2024	0.8000
27 Mar 2024	0.8000
28 Dec 2023	0.8000